eXoZymes (EXOZ) Investor presentation summary

Technology and platform overview

• Cell-free, AI-enhanced biomanufacturing platform enables production of rare, high-purity natural products at scale.

• Platform bypasses traditional cell-based bottlenecks, offering rapid, scalable, and controllable manufacturing.

• Enzymes are engineered to function outside cells, allowing for high yields and purity unattainable by fermentation or extraction.

• Demonstrated ability to move from concept to pilot scale in under a year, with third-party validation.

Product pipeline and market opportunity

• Focus on two flagship programs: NCT (metabolic health) and novel cannabinoids, each targeting $100B+ TAM.

• NCT produced at 100x natural scale, >99% yield and 99.6% purity, with both nutraceutical and pharma applications.

• Cannabinoids manufactured at GMP purity, including new-to-nature, non-intoxicating variants for pharma markets.

• Pipeline enables rapid prototyping, incubation, acceleration, and commercialization in months, not years.

Commercialization and go-to-market strategy

• Capital-light model leverages tech transfer to CMOs, partnerships, JVs, and spinouts for scale-up and market entry.

• Retains IP ownership while capturing value through equity, licensing, and royalties.

• Commercial launch planned for both OTC and pharma markets, with initial NCT product launch expected 2027/2028.